Science

Diego A. Díaz García: HER3 – From Understudy to Key Target

Diego A. Díaz García/X

May 6, 2025, 11:07

Diego A. Díaz García: HER3 – From Understudy to Key Target

Diego A. Díaz García, Medical Oncologist , CEO and Founder at CánCare, shared an article on X:

“HER3: from understudy to key target.

Once overlooked, HER3 is now gaining ground in cancer therapy. New strategies including ADCs & bispecifics show promise—like FDA-approved Zenocutuzumab for NRG1+ NSCLC & pancreatic cancer.

This article offers an essential overview of:

HER3 biology, mutations, and expression in tumors.
Its role in therapy resistance and immune interactions.
Emerging HER3-directed therapies and their potential across cancer types.”

Diego A. Díaz García: HER3 - From Understudy to Key Target

Emerging importance of HER3 in tumorigenesis and cancer therapy.

Authors: Joan T. Garrett, Salomon Tendler, Wasim Feroz, Mary Kate Kilroy, Helena Yu.

You can read the Full Article on Journal of Nature Reviews Clinical Oncology.

Diego A. Díaz García: HER3 - From Understudy to Key Target

More posts featuring Diego A. Díaz García.

ADCs CánCare cancer cancer therapy Diego A. Díaz García FDA fight against cancer Global fight against cancer Helena Yu HER3 Joan T. Garrett Key Target Mary Kate Kilroy NRG1 NSCLC OncoDaily Oncology Pancreatic Cancer Salomon Tendler therapy resistance tumorigenesis Understudy Wasim Feroz zenocutuzumab

USA vs Europe: Who Does Cancer Screening Better?

A Call for Peace from the Frontlines of Pediatric Oncology by the POEM Group

Servier Acquires Precision Therapy for Acute Leukemias from BioNova Pharmaceuticals

Penn Medicine: Cancer Center Near Me

Elevating Childhood Cancer and Catastrophic Diseases in the Global NCD Agenda: Joint Call to Action